Semaglutide — the molecule behind Ozempic and Wegovy — produced one of the most striking results in the history of obesity medicine. In the landmark STEP 1 trial, adults with obesity who took the drug for 68 weeks lost an average of 14.9 percent of their body weight, compared with just 2.4 percent on placebo.[1] That is a scale of weight loss that used to require surgery. But as these drugs moved from clinical trials into the lives of millions of people, a quieter question started showing up in the research: what kind of weight is coming off? Not all of it is fat.
Over the past two years, a run of careful body-composition studies has put numbers on something clinicians had long suspected. When you lose weight fast — on any diet, drug or operation — part of what you lose is lean tissue: muscle, along with the water, connective tissue and organ mass that scientists lump together as “fat-free mass.” The interesting, and genuinely unsettled, question is how much of that matters for how well you age. Here is what the evidence actually shows, minus both the panic and the dismissiveness.
Putting a number on the loss
The most rigorous look so far came from a 2024 systematic review and network meta-analysis that pooled 22 randomized trials covering 2,258 people. It found that GLP-1 drugs reduced total body weight by about 3.6 kg on average, fat mass by roughly 3 kg, and lean mass by around 0.9 kg — meaning lean tissue made up approximately a quarter of the total weight lost.[2] A separate clinical review put the ceiling higher, noting that in some settings up to 40 percent of the weight lost on GLP-1 therapy can come from fat-free mass.[3] Those two figures aren't contradictory; they reflect different populations, drugs, doses and ways of measuring.
The same meta-analysis surfaced a detail that rarely makes the headlines. Not all of these drugs behave identically. Liraglutide — an older, less potent daily GLP-1 — was the only one that produced meaningful weight loss without a statistically significant drop in lean mass. The most powerful agents, tirzepatide and high-dose semaglutide, drove the greatest weight and fat loss but were among the least effective at sparing lean tissue.[2] In other words, the drugs that melt away the most fat may also be the ones that demand the most attention to muscle. Real-world data are beginning to echo the trials: a 2025 analysis of people using compounded semaglutide outside of a study setting found the same broad pattern of fat and lean mass coming off together.[7]
Why some of the loss is nothing to fear
Here is the part that gets lost in the alarm. Losing some lean tissue while shedding a large amount of fat is normal, expected and often healthy. A bigger body — even a body carrying excess fat — builds extra muscle just to move itself around, the way a heavier backpack makes your legs stronger. When the load comes off, some of that supporting muscle is no longer needed and the body lets it go. That is different from wasting away.
The distinction the newest research keeps stressing is between fat-free mass and skeletal muscle specifically. Fat-free mass includes water, glycogen, connective tissue and organs — not just muscle — so a drop in the scale number for lean mass overstates how much actual muscle is disappearing.[3] Reassuringly, the network meta-analysis found that while absolute lean mass fell, participants' lean mass as a percentage of body weight didn't meaningfully change — their body composition, proportionally, stayed roughly the same.[2] For a healthy younger adult with plenty of muscle to spare, that is probably fine.
The concern sharpens with age. Muscle is not just for lifting things; it is a metabolic organ that soaks up blood sugar, supports bone, cushions falls and predicts how independently you'll live in your seventies and eighties. A 2024 review examining how weight loss affects fat-free mass, muscle, bone and even the blood-forming system warned that the goal for the new generation of fat-loss drugs should be exactly that — maximal fat reduction with lean mass preservation, not lean mass indifference.[5] Someone who is already close to sarcopenia — the age-related loss of muscle and strength — has far less margin to give away, and losing muscle in your sixties is much harder to reverse than losing it in your thirties.
The two defenses that actually work
The good news is that the muscle problem is largely a solvable one, and the solutions are unglamorous. Two interventions have the strongest support, and they are the same two that protect muscle during any weight loss.
The first is resistance training. A 2024 review in Diabetes Care made the case directly in its title — asking whether resistance exercise can optimize the body-composition changes from incretin-based drugs — and concluded that lifting weights is a logical and promising way to steer more of the loss toward fat.[4] You don't need a gym or heavy barbells; two or three sessions a week of progressively challenging effort, using bands, machines or your own body weight, is enough to signal to muscle that it is still needed.
The second is protein. Adequate protein intake, generally cited in the range of 1.2 to 1.6 grams per kilogram of body weight per day, gives muscle the raw material to rebuild — and this matters more on GLP-1 drugs precisely because they suppress appetite so effectively that people often under-eat protein without noticing.[3] The same clinical review notes that when training and protein aren't enough, specific nutrients including creatine, leucine and other branched-chain amino acids, omega-3 fatty acids and vitamin D may offer additional support for muscle.[3] None of these is a magic bullet, and the evidence for them specifically during GLP-1 therapy is still described as mixed — but they are low-risk, and they align with everything we know about preserving muscle as we age. It is also worth losing weight at a sustainable pace rather than chasing the fastest possible number on the scale, since slower loss tends to protect lean tissue.
The next generation: drugs that protect muscle
The most futuristic response to the muscle question is to build the protection into the pharmacology itself. Researchers are testing drugs that block the activin and myostatin signaling pathways — the body's built-in brakes on muscle growth. Release those brakes, the thinking goes, and you can lose fat while holding on to, or even adding, muscle. In a 2024 preclinical study, blocking the activin type II receptors with an antibody preserved skeletal muscle mass and enhanced fat loss when combined with a GLP-1 drug — a result that turned heads because it suggested the two effects could be stacked.[6] The most advanced of these agents in people, bimagrumab, is now being studied alongside semaglutide, and reviews list this class as one of the most promising ways to keep muscle during pharmacological weight loss.[3]
It is genuinely exciting science, and it may reshape how these drugs are prescribed within a few years. But it is not here yet, and combining powerful metabolic drugs always raises new safety questions that only long trials can answer. For anyone taking a GLP-1 today, the muscle-sparing drug of the future is no substitute for the resistance band and the protein on your plate right now.
An honest verdict
The muscle story is not a reason to fear GLP-1 drugs, which remain among the most effective tools medicine has ever had for obesity and its long list of downstream harms. It is a reason to use them thoughtfully. A large fraction of the lean mass you lose alongside a lot of fat is normal and even beneficial — but muscle is the currency of healthy aging, and it is far easier to protect than to rebuild. If you are on one of these drugs, or considering one, treat resistance training and protein not as optional extras but as part of the prescription. The weight you lose should be the weight you want gone. The strength you keep is the part that decides how well the next few decades go.
Common questions
Does Ozempic make you lose muscle?
Some muscle loss is expected with any significant weight loss, and GLP-1 drugs are no exception. In pooled trial data, lean mass made up roughly a quarter of the total weight lost, and reviews note that as much as 40 percent of weight loss can come from fat-free mass in some settings. A large part of that lean loss is normal and even healthy when you shed a lot of fat. The concern is the muscle specifically, and whether it is being protected with exercise and protein.
How do you keep muscle while taking a GLP-1 drug?
The two best-supported strategies are resistance training two to three times a week and eating enough protein, generally around 1.2 to 1.6 grams per kilogram of body weight per day. Reviews also point to creatine, leucine-rich or branched-chain amino acids, omega-3 fatty acids and vitamin D as possible aids, and to losing weight gradually rather than as fast as possible. Never stop a prescribed medication without talking to your doctor.
Are newer weight-loss drugs better at protecting muscle?
That is the direction the field is moving. Drugs that block the activin and myostatin pathways, such as bimagrumab, have preserved or even increased muscle while enhancing fat loss in early studies, and are being tested alongside GLP-1 drugs. It is promising, but these combinations are still experimental and not yet standard care.